Redmond Asset Management LLC cut its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report) by 44.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,567 shares of the company’s stock after selling 88,636 shares during the period. Redmond Asset Management LLC’s holdings in Cellebrite DI were worth $1,256,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nine Ten Capital Management LLC lifted its holdings in shares of Cellebrite DI by 19.8% during the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after buying an additional 682,933 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Cellebrite DI by 93.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after buying an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Cellebrite DI by 14.7% in the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock worth $39,420,000 after buying an additional 365,700 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock worth $29,712,000 after buying an additional 545,334 shares during the last quarter. Finally, Meitav Investment House Ltd. increased its holdings in Cellebrite DI by 34.4% in the first quarter. Meitav Investment House Ltd. now owns 1,954,846 shares of the company’s stock worth $26,938,000 after buying an additional 500,000 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Cellebrite DI news, CRO Marcus Jewell sold 12,562 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total transaction of $141,196.88. Following the completion of the sale, the executive owned 427,128 shares of the company’s stock, valued at $4,800,918.72. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David Barter sold 12,134 shares of the company’s stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $11.21, for a total value of $136,022.14. Following the sale, the chief financial officer directly owned 322,085 shares of the company’s stock, valued at $3,610,572.85. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 196,870 shares of company stock valued at $2,797,143 over the last 90 days. 5.70% of the stock is currently owned by insiders.
Analyst Ratings Changes
CLBT has been the topic of several recent research reports. DA Davidson reaffirmed a “buy” rating and set a $15.00 price objective on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings downgraded shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a research note on Friday, August 14th. Finally, Lake Street Capital reduced their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cellebrite DI has an average rating of “Moderate Buy” and a consensus target price of $16.70.
Read Our Latest Analysis on CLBT
Cellebrite DI Stock Performance
CLBT opened at $11.92 on Thursday. The company has a market cap of $2.97 billion, a PE ratio of 54.18, a price-to-earnings-growth ratio of 1.85 and a beta of 1.14. The stock has a 50-day moving average of $11.46 and a 200-day moving average of $13.50. Cellebrite DI Ltd. has a 52-week low of $9.58 and a 52-week high of $19.98.
About Cellebrite DI
Cellebrite DI Ltd. (NASDAQ: CLBT) provides digital intelligence and digital forensics solutions that help organizations collect, preserve, analyze and manage data from mobile devices, computers, cloud environments and other digital sources. Its customers include law enforcement agencies, public safety organizations, government and intelligence bodies, military units, and corporate security and investigation teams.
The company’s offerings include tools for accessing and extracting digital evidence, case and evidence management, and investigative analytics.
Featured Articles
- Five stocks we like better than Cellebrite DI
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT – Free Report).
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
